Arcutis Biotherapeutics (ARQT) said Friday that its Arcutis Canada subsidiary has received regulatory approval from Health Canada for Zoryve topical foam 0.3% to treat seborrheic dermatitis in patients aged 9 and older.
The approval was based on data from a phase 3 study, along with findings from a phase 2 study, a long-term open-label extension study, and a phase 1 pharmacokinetic study, the biopharmaceutical company said.
Price: 9.63, Change: +0.14, Percent Change: +1.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.